<DOC>
	<DOCNO>NCT02279407</DOCNO>
	<brief_summary>This study double-blind randomize , placebo-controlled , parallel-group , 12 week study perform 5 centre Sweden ass effect Omega-3 carboxylic acid dapagliflozin liver fat patient Type 2 diabetes fatty liver ( &gt; 5.5 % measure magnetic resonance imaging ( MRI ) )</brief_summary>
	<brief_title>A Study Investigate Effects Omega-3 Carboxylic Acids Dapagliflozin Liver Fat Content Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<criteria>Provision inform consent prior study specific procedure ; Men woman ≥40 year ≤75 year suitable vein cannulation repeat venepuncture ; Have liver fat content assess MRI &gt; 5.5 % ; Diagnosis Type 2 diabetes since least 6 month accordance WHO criterion . Any condition MRI contraindicate , limited , pacemaker claustrophobia ; Diagnosis sign Type 1 diabetes ( e.g . history positive islet antibody ) ; Creatinine clearance &lt; 60 mL/min screening ( CockcroftGault formula ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>omega-3 carboxylic acid</keyword>
</DOC>